English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond. This post hoc analysis explored the relationship between early disease activity changes and the achievement of low disease activity ( LDA ) and remission targets with tofacitinib.    Methods  Data were from 2 randomized, double‐blind, phase  III  studies. In the  ORAL  Start trial, methotrexate ( MTX )–naive patients received tofacitinib 5 or 10 mg twice daily, or  MTX , for 24 months. In the placebo‐controlled  ORAL  Standard trial,  MTX  inadequate responder patients received tofacitinib 5 or 10 mg twice daily or adalimumab 40 mg every 2 weeks, with  MTX , for 12 months. Probabilities of achieving  LDA  (using a Clinical Disease Activity Index [ CDAI ] score ≤10 or the 4‐component Disease Activity Score in 28 joints using the erythrocyte sedimentation rate [ DAS 28‐ ESR ] ≤3.2) at months 6 and 12 were calculated, given failure to achieve threshold improvement from baseline (change in  CDAI  ≥6 or  DAS 28‐ ESR  ≥1.2) at month 1 or 3.    Results  In  ORAL  Start, 7.2% and 5.4% of patients receiving tofacitinib 5 and 10 mg twice daily, respectively, failed to show improvement in the  CDAI  ≥6 at month 3; of those who failed, 3.8% and 28.6%, respectively, achieved month 6  CDAI ‐defined  LDA . In  ORAL  Standard, 18.8% and 17.5% of patients receiving tofacitinib 5 and 10 mg twice daily, respectively, failed to improve  CDAI  ≥6 at month 3; of those who failed, 0% and 2.9%, respectively, achieved month 6  CDAI ‐defined  LDA . Findings were similar when considering improvements at month 1 or  DAS 28‐ ESR  thresholds.    Conclusion  In patients with an inadequate response to  MTX , lack of response to tofacitinib after 1 or 3 months predicted a low probability of achieving  LDA  at month 6. Lack of an early response may be considered when deciding whether to continue treatment with tofacitinib.

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6